Community evaluation of VECTRON™ T500 (broflanilide) for indoor residual spraying for malaria vector control in Siaya county, Kenya Authors: Celestine N. Wekesa, Brian Polo, Margaret Muchoki, Seline Omondi, Mathew Kipsum, Bernard Abong’o, Maxwell G. Machani, Teresa Bange, Ismael Abbey, Paul Kiptoo, Patrick Mburugu, Kibor Keitany, David Sang, Edith Ramaita, Eric Ochomo Published: 2025 ABSTRACT BackgroundIndoor residual spraying (IRS) remains a core malaria vector control intervention, but widespread insecticide resistance threatens its effectiveness. VECTRON™ T500, containing broflanilide, represents a novel IRS product with a new mode of action targeting GABA receptors.MethodsA two-arm non-inferiority study was conducted in Bar Olengo, Siaya County, Kenya, between June and November 2024. Twenty-five structures per arm were sprayed with either VECTRON™ T500 (100 mg a.i/m2) or Actellic™ 300CS (1 g a.i/m2), with five water-sprayed controls. Residual efficacy was assessed using world health organization (WHO) cone bioassays with pyrethroid-resistant Anopheles gambiae sensu stricto (s.s.) Bungoma strain and susceptible Kisumu strain monthly for six months. Wild vector susceptibility to insecticides, community acceptability, and adverse events were evaluated.ResultsVECTRON™ T500 maintained significantly higher mortality than Actellic™ 300CS throughout six months on both wall types. Against resistant An. gambiae s.s. Bungoma strain, VECTRON™ T500 achieved 98.73 ± 3.51% mortality (95% CI 97.95–99.51%) compared to 80.22 ± 11.23% for Actellic™ 300CS (95% CI 77.72–82.72%; t₇₈ = − 10.15, p < 0.001, Cohen's d = 2.27). For susceptible Kisumu strain, VECTRON™ T500 maintained 100% mortality versus 89.60 ± 6.34% for Actellic™ 300CS (95% CI 88.19–91.01%; t₇₈ = 10.53, p < 0.001, Cohen's d = 2.38). Actellic™ 300CS efficacy declined below 80% after month 4, while VECTRON™ T500 remained > 95% effective throughout. Wild An. gambiae sensu lato (s.l.) and Anopheles funestus s.l. showed 100% susceptibility to broflanilide with no cross-resistance detected. No adverse events occurred in VECTRON™ T500 households versus 8% (12/150) in Actellic™ 300CS households. Community acceptance was 100% for VECTRON™ T500 versus 99.33% (149/150) for Actellic™ 300CS, though this difference was not statistically significant.ConclusionsVECTRON™ T500 demonstrated superior residual efficacy, excellent safety profile, and high community acceptance compared to Actellic™ 300CS. Its novel mode of action and absence of cross-resistance to pirimiphos-methyl and pyrethroids make it valuable for insecticide resistance management in malaria vector control programmes. Background Vector control has significantly reduced malaria transmission across endemic regions with varying epidemiological conditions [1]. Indoor residual spraying (IRS), involving treatment of interior house surfaces with residual insecticide formulations, remains a core intervention as demonstrated during the global malaria eradication program [2]. According to World Health Organization (WHO) reports, IRS protected approximately 1.6% of at-risk populations globally in malaria endemic countries with 88.4% coverage of target structures [3]. IRS targets adult mosquitoes feeding indoors (endophagic) and resting indoors (endophilic) through repellency effects or by killing them when they contact treated surfaces with lethal insecticide concentrations [4]. Massive vector population declines and reduced longevity from IRS effectively reduce malaria transmission through decreased vectorial capacity [5]. Sustainable IRS implementation has substantially impacted malaria prevalence globally, especially in high transmission areas [6]. WHO-recommended insecticide classes for IRS include pyrethroids, organochlorines, carbamates, organophosphates, neonicotinoids, and pyrroles [7]. Prolonged reliance on single insecticide classes increases resistance, reducing IRS efficacy [8]. Resistance to organophosphates, pyrethroids, carbamates, and organochlorines has been reported globally with varying intensities across WHO regions [9]. To mitigate resistance development, the WHO recommends four strategies (mixtures, rotations, mosaics, and combinations) to preserve vector susceptibility [10]. Available insecticidal products are insufficient to meet growing malaria vector control challenges due to limited alternative insecticides [11]. Consistent innovation of new products that overcome resistance, have longer residual effects, and maintain efficacy in high transmission areas continues [11]. Conventional IRS insecticides display two major biochemical modes of action: sodium channel disruption (pyrethroids and organochlorines) and acetylcholinesterase inhibition (organophosphates and carbamates) [12]. Next-generation insecticides include chlorfenapyr (pyrrole class) with distinctive oxidative phosphorylation uncoupling in insect mitochondria [13], neonicotinoids like clothianidin acting through nicotinic acetylcholine receptor overstimulation [14], indoxacarb blocking sodium ion channels, and insect growth regulators disrupting development through juvenile hormone mimicking or inhibition [12, 16]. VECTRON™ T500, a wettable powder formulation containing broflanilide produced by Mitsui Chemicals Crop & Life Solutions, Inc. (MCCLS), is among the most recently WHO-prequalified IRS insecticides [15]. Broflanilide contains a meta-diamide chemical structure offering a novel mode of action against malaria vectors compared to existing IRS insecticide classes [16]. It functions by inhibiting neurotransmission through non-competitive antagonism of γ-aminobutyric acid (GABA) receptors on chloride-gated channels, causing hyperexcitation, convulsion, and death [12, 16]. Meta-diamides and isoxazolines (Group 30 insecticides—GABA-gated chloride channel allosteric modulators) are characterized by long residual activity and effectiveness against pyrethroid-resistant insects on different substrates [17]. Broflanilide's novel GABA receptor targeting provides significant resistance management advantages, representing a distinctive class creating opportunities for effective rotation strategies [12, 16]. This unique mechanism may explain the absence of cross-resistance with existing resistance mechanisms in African malaria vectors [18, 19]. Comparing VECTRON™ T500 with Actellic™ 300CS (pirimiphos-methyl) is particularly relevant as the latter represents the first-in-class organophosphate widely deployed for IRS in Kenya since 2017 following widespread pyrethroid resistance development [20]. This study, required by Kenya's Pest Control Products Board (PCPB) for VECTRON™ T500 registration, evaluated residual efficacy compared to Actellic™ 300CS on pyrethroid-resistant and susceptible Anopheles gambiae sensu stricto (s.s.) strains, with secondary endpoints including community acceptability and safety. Methods Study area This study was conducted in Bar Olengo location (− 0.0728262°N, 34.6699246°E), Bondo sub-county, Siaya County, Kenya. Siaya County, located in western Kenya and bordered by Lake Victoria, provides favourable mosquito breeding environments. The county has high malaria prevalence, ranking second nationally [21, 22]. Current vector control relies solely on pyrethroid-only insecticide-treated nets (ITNs). The area receives 800–2000 mm annual bimodal rainfall with 60–80% humidity. Annual mean temperatures range 30–35 °C, favoring malaria vector survival and breeding [23]. Principal vectors are Anopheles funestus s.s., An. gambiae s.s., and Anopheles arabiensis, all exhibiting high-intensity pyrethroid resistance. Main economic activities include fishing, rice farming, livestock raising, small-scale trading, and gold mining. Study design and randomization A longitudinal two-arm evaluation study was conducted between June and November 2024. The study area was stratified by village (Waga and Bungu), then by wall type (mud and cement) to ensure balanced representation. Using computer-generated random numbers, 25 eligible structures from each village were selected with equal wall type allocation. VECTRON™ T500 was applied in Waga village while Actellic™ 300CS was applied in Bungu village, with 5 randomly selected structures per village serving as negative controls (water-sprayed). Sample size calculation Based on previous IRS efficacy studies and assuming 90% mortality for the positive control product (pirimiphos methyl) with 80% power to detect a 10% difference at 5% significance level, 25 structures per arm provided adequate power for non-inferiority testing. Test products and application VECTRON™ T500: Wettable powder containing 50% broflanilide active ingredient, supplied in 50 g sachets and applied at 100 mg a.i/m2. Full safety information, toxicological reports, and certificates of analysis were provided by MCCLS. Actellic™ 300CS: Pirimiphos-methyl applied at 1 g a.i/m2 as positive control. Residual efficacy assessment WHO cone bioassays followed standard guidelines [24] at 7 days post-spraying for quality assessment, then monthly for six months evaluating residual efficacy. Ten households per village were randomly selected, stratified by wall type (5 mud, 5 cement). Cone bioassays used 2–5-day-old non-blood-fed females from two laboratory colonies:Pyrethroid-resistant An. gambiae s.s. Bungoma strain (elevated P450 enzymes, ace-1 mutations, kdr polymorphisms)Susceptible An. gambiae s.s. Kisumu strain Pyrethroid-resistant An. gambiae s.s. Bungoma strain (elevated P450 enzymes, ace-1 mutations, kdr polymorphisms) Pyrethroid-resistant An. gambiae s.s. Bungoma strain (elevated P450 enzymes, ace-1 mutations, kdr polymorphisms) Susceptible An. gambiae s.s. Kisumu strain Susceptible An. gambiae s.s. Kisumu strain Bioassays were conducted at three heights (0.5, 1.0, 1.5 m) on different walls per room. Two cones per test point exposed 10 mosquitoes each for 30 min. Mosquitoes were aspirated into labelled cups; knockdown was recorded at 60 min, mortality monitored at 24, 48, and 72 h under controlled conditions (27 ± 2 °C, 80 ± 10% relative humidity). Control assays on unsprayed surfaces applied Abbott's formula when control mortality exceeded 5% but remained below 20%. Assays with ≥ 20% control mortality were repeated. Wild vector susceptibility testing Comprehensive bioassays established insecticide resistance status. An. gambiae s.l. larvae were collected from multiple breeding sites before spraying and reared to adulthood. Blood-fed adult An. funestus were collected using mouth aspirators for F₀ generation testing. Standard WHO tube bioassays used diagnostic concentrations: deltamethrin (0.05%), permethrin (0.75%), alpha-cypermethrin (0.05%), and pirimiphos-methyl (0.25%). Resistance intensity bioassays used 5 × and 10 × diagnostic concentrations. Synergist assays exposed mosquitoes to 4% piperonyl butoxide (PBO) for 1 h before pyrethroid exposure [39]. CDC bottle bioassays for broflanilide and pirimiphos-methyl followed established methods [25] with discriminating concentrations: 6 μg/bottle with 800 ppm Mero adjuvant for broflanilide and 20 μg/bottle for pirimiphos-methyl. Knockdown was recorded at 60 min, mortality at 24 h for pyrethroids and pirimiphos-methyl, 48 h for broflanilide. Four replicates with 20–25 unfed mosquitoes per replicate were used per insecticide. Molecular assays identified An. gambiae complex [26] and An. funestus complex [27] species. Resistance status classification followed WHO criteria: ≥ 98% mortality (susceptible), 90–97% (possible resistance), < 90% (confirmed resistance). Community acceptability and adverse events Baseline questionnaires captured pre-intervention health status of the sprayers and the consented community members. Questionnaires were administered to household heads on spraying day, one week post-spraying, and monthly for six months, determining factors influencing VECTRON™ T500 acceptability compared to Actellic™ 300CS. User acceptability was calculated as the ratio of household refusals to total structures sprayed, recording refusal reasons. Three months post-intervention, 20 audio-recorded in-depth interviews assessed product acceptability among end-users and spray operators. Eight households per arm were randomly interviewed, evenly split between wall types. Four spray operators familiar with both products explored knowledge, perceptions, and experiences. Apparently healthy sprayers were enrolled after pre-spray questionnaire screening. Daily post-spray questionnaires captured adverse events experienced during and after spraying. Household heads received adverse events questionnaires for six months in both intervention areas and controls. Both sprayers and householders were encouraged to report suspected insecticide-related symptoms immediately. Statistical analysis Data collection used CommCare™ application with structured questionnaires. Residual efficacy analysis calculated mortality means from both arms and negative controls. Independent t-tests determined mortality differences with effect sizes calculated using Cohen's d. Control mortality > 5% was adjusted using Abbott's formula. Susceptibility test data analysed mortality means from each insecticide tested. Community acceptability was calculated as mean household refusals to total sprayed structures, analysed using independent t-tests. In-depth interview audio records were transcribed and coded using NVivo version 14. Codebook-guided initial deductive coding while inductive coding captured emerging themes. Thematic synthesis identified patterns across codes and respondent categories. Adverse events were calculated by finding means of reported symptoms and analyzed using independent t-tests. Statistical analysis and visualization used R version 4.4.0. Ethical and regulatory considerations This study was conducted under PCPB trial permit PCPB/Eval/Vol.I/24/44. The protocol was approved by Kenya Medical Research Institute's Scientific and Ethics Review Unit (SERU 4536). Community consent was obtained from Siaya County health department, local chiefs, village leaders, and community health promoters. Written informed consent was obtained from household heads and sprayers. Results Residual efficacy VECTRON™ T500 consistently maintained higher mortality than Actellic™ 300CS throughout the six-month period on both wall surfaces. For resistant An. gambiae s.s. Bungoma strain, VECTRON™ T500 induced 98.73 ± 3.51% mortality compared to 80.22 ± 11.23% for Actellic™ 300CS (t78 = − 10.15, p < 0.001, Cohen's d = 2.27) (Fig. 1). For susceptible An. gambiae s.s. Kisumu strain, VECTRON™ T500 maintained 100% mortality versus 89.60 ± 6.34% for Actellic™ 300CS (t78 = 10.53, p < 0.001, Cohen's d = 2.38) (Fig. 2).Fig. 1Comparison of 24-h mortality rates (with 95% confidence intervals) following WHO cone bioassay exposure to VECTRON™ T500 and Actellic™ 300CS over six months. VECTRON™ T500 maintained > 95% mortality while Actellic™ 300CS fell below the 80% WHO threshold after month 4. Abbott's formula was applied to correct for control mortality > 5%Fig. 2Comparison of 24-h mortality rates (with 95% confidence intervals) following WHO cone bioassay exposure to VECTRON™ T500 and Actellic™ 300CS over six months Comparison of 24-h mortality rates (with 95% confidence intervals) following WHO cone bioassay exposure to VECTRON™ T500 and Actellic™ 300CS over six months. VECTRON™ T500 maintained > 95% mortality while Actellic™ 300CS fell below the 80% WHO threshold after month 4. Abbott's formula was applied to correct for control mortality > 5% Comparison of 24-h mortality rates (with 95% confidence intervals) following WHO cone bioassay exposure to VECTRON™ T500 and Actellic™ 300CS over six months Critically, Actellic™ 300CS efficacy declined below the WHO-recommended 80% threshold after month 4 for resistant mosquitoes, dropping to 76.2% in month 5 and 71.8% in month 6. VECTRON™ T500 maintained > 95% mortality throughout the entire evaluation period, never falling below 96.5% for any strain or time point (Table 1).Table 1Monthly mortality rates (mean ± standard deviation) of pyrethroid-resistant An. gambiae s.s. Bungoma strain and susceptible An. gambiae s.s. Kisumu on Vectron T500 and Actellic 300CSMonthVECTRON™ T500Actellic™ 300CSResistant (%)Susceptible (%)Resistant (%)Susceptible (%)1100.0 ± 0.0100.0 ± 0.092.3 ± 4.296.8 ± 2.1299.2 ± 1.8100.0 ± 0.088.7 ± 6.894.2 ± 3.6398.9 ± 2.1100.0 ± 0.085.4 ± 8.191.5 ± 4.8498.1 ± 2.8100.0 ± 0.079.8 ± 9.288.7 ± 5.2597.8 ± 3.2100.0 ± 0.076.2 ± 11.485.3 ± 6.8696.5 ± 3.9100.0 ± 0.071.8 ± 12.682.1 ± 7.4WHO cone bioassays performed on treated walls with VECTRON™ T500 (100 mg a.i./m2) and Actellic™ 300CS (1000 mg a.i./m2) over six months post-application. Mortality was assessed at 72 h post-exposure. Control mortality > 5% was corrected using Abbott's formula. WHO efficacy threshold for IRS products is ≥ 80% mortality Table 1Monthly mortality rates (mean ± standard deviation) of pyrethroid-resistant An. gambiae s.s. Bungoma strain and susceptible An. gambiae s.s. Kisumu on Vectron T500 and Actellic 300CSMonthVECTRON™ T500Actellic™ 300CSResistant (%)Susceptible (%)Resistant (%)Susceptible (%)1100.0 ± 0.0100.0 ± 0.092.3 ± 4.296.8 ± 2.1299.2 ± 1.8100.0 ± 0.088.7 ± 6.894.2 ± 3.6398.9 ± 2.1100.0 ± 0.085.4 ± 8.191.5 ± 4.8498.1 ± 2.8100.0 ± 0.079.8 ± 9.288.7 ± 5.2597.8 ± 3.2100.0 ± 0.076.2 ± 11.485.3 ± 6.8696.5 ± 3.9100.0 ± 0.071.8 ± 12.682.1 ± 7.4WHO cone bioassays performed on treated walls with VECTRON™ T500 (100 mg a.i./m2) and Actellic™ 300CS (1000 mg a.i./m2) over six months post-application. Mortality was assessed at 72 h post-exposure. Control mortality > 5% was corrected using Abbott's formula. WHO efficacy threshold for IRS products is ≥ 80% mortality Monthly mortality rates (mean ± standard deviation) of pyrethroid-resistant An. gambiae s.s. Bungoma strain and susceptible An. gambiae s.s. Kisumu on Vectron T500 and Actellic 300CS WHO cone bioassays performed on treated walls with VECTRON™ T500 (100 mg a.i./m2) and Actellic™ 300CS (1000 mg a.i./m2) over six months post-application. Mortality was assessed at 72 h post-exposure. Control mortality > 5% was corrected using Abbott's formula. WHO efficacy threshold for IRS products is ≥ 80% mortality Residual efficacy of the IRS products on different wall types Mortality means for resistant An. gambiae s.s. Bungoma strain were higher with VECTRON™ T500 on both cement (98.66 ± 3.56%) and mud (100%) walls compared to Actellic™ 300CS on cement (78.82 ± 15.57%) and mud (77.75 ± 11.69%) walls. Statistically significant differences existed for cement walls (t12 = 3.286, p = 0.007) and mud walls (t12 = 5.037, p < 0.001). Mortality was observed to fall below 80% at month 4 in the Actellic™ 300CS arm (Fig. 3).Fig. 3Mean adjusted mortality rates comparing VECTRON™ T500 and Actellic™ 300CS performance on mud and cement wall surfaces for both resistant and susceptible mosquito strains Mean adjusted mortality rates comparing VECTRON™ T500 and Actellic™ 300CS performance on mud and cement wall surfaces for both resistant and susceptible mosquito strains For susceptible An. gambiae s.s. Kisumu strain, VECTRON™ T500 maintained 100% mortality on both wall types compared to Actellic™ 300CS cement (88.01 ± 8.5%) and mud (86.65 ± 6.64%) performance. Significant differences were observed for cement (t12 = 3.700, p = 0.003) and mud (t12 = 5.318, p < 0.001) walls (Fig. 3). Susceptibility of wild Anopheles mosquitoes to Broflanilide and pirimiphos methyl Among 2400 wild vectors tested, molecular identification of 400 specimens revealed: 200 An. funestus sensu lato (s.l.) (98% An. funestus s.s., 2% Anopheles leesoni), 200 An. gambiae s.l. consisting 92% Anopheles arabiensis, and 2% An. gambiae s.s, the rest were unamplified. CDC bottle bioassays showed Broflanilide induced 100% mortality in both An. gambiae s.l. and An. funestus s.l. with delayed mortality at 48 h where all mosquitoes had died, indicating no cross-resistance detection with pirimiphos-methyl and pyrethroids. Pirimiphos-methyl similarly induced 100% mortality at 24 h post-exposure (Fig. 4, Table 2).Fig. 4Mean percentage mortality of field-collected An. gambiae s.l. and An. funestus s.l. after exposure to broflanilide and pirimiphos-methyl in CDC bottle bioassaysTable 2Susceptibility of field-collected An. gambiae s.l. and An. funestus s.l. to broflanilide, pirimiphos-methyl, and deltamethrinSpeciesInsecticideMortality (%)95% CIStatusAn. gambiae s.lBroflanilide100100.0–100.0SusceptibleAn. funestus s.lBroflanilide100100.0–100.0SusceptibleAn. gambiae s.lPirimiphos-methyl100100.0–100.0SusceptibleAn. funestus s.lPirimiphos-methyl100100.0–100.0SusceptibleAn. gambiae s.lDeltamethrin23.4 ± 8.219.8–27.0ResistantAn. funestus s.lDeltamethrin31.2 ± 9.626.4–36.0ResistantAn. gambiae s.lDeltamethrin + PBO100.0 ± 0.0100.0–100.0SusceptibleAn. funestus s.lDeltamethrin + PBO89.3 ± 6.485.1–93.5ResistantSusceptibility was determined using WHO bottle bioassays and CDC bottle bioassays. Mosquitoes were exposed to diagnostic concentrations: broflanilide (6 μg/bottle with 800 ppm Mero adjuvant), pirimiphos-methyl (20 μg/bottle), and deltamethrin (12.5 μg/bottle). Piperonyl butoxide (PBO) synergist assays used 4% PBO pre-exposure for 1 h before deltamethrin exposure. Mortality was recorded at 24 h for deltamethrin and pirimiphos-methyl, and 48 h for broflanilide. Resistance status classification follows WHO criteria: ≥ 98% mortality (susceptible), 90–97% (possible resistance), < 90% (confirmed resistance). Data represent mean percentage mortality ± standard deviation with 95% confidence intervals Mean percentage mortality of field-collected An. gambiae s.l. and An. funestus s.l. after exposure to broflanilide and pirimiphos-methyl in CDC bottle bioassays Table 2Susceptibility of field-collected An. gambiae s.l. and An. funestus s.l. to broflanilide, pirimiphos-methyl, and deltamethrinSpeciesInsecticideMortality (%)95% CIStatusAn. gambiae s.lBroflanilide100100.0–100.0SusceptibleAn. funestus s.lBroflanilide100100.0–100.0SusceptibleAn. gambiae s.lPirimiphos-methyl100100.0–100.0SusceptibleAn. funestus s.lPirimiphos-methyl100100.0–100.0SusceptibleAn. gambiae s.lDeltamethrin23.4 ± 8.219.8–27.0ResistantAn. funestus s.lDeltamethrin31.2 ± 9.626.4–36.0ResistantAn. gambiae s.lDeltamethrin + PBO100.0 ± 0.0100.0–100.0SusceptibleAn. funestus s.lDeltamethrin + PBO89.3 ± 6.485.1–93.5ResistantSusceptibility was determined using WHO bottle bioassays and CDC bottle bioassays. Mosquitoes were exposed to diagnostic concentrations: broflanilide (6 μg/bottle with 800 ppm Mero adjuvant), pirimiphos-methyl (20 μg/bottle), and deltamethrin (12.5 μg/bottle). Piperonyl butoxide (PBO) synergist assays used 4% PBO pre-exposure for 1 h before deltamethrin exposure. Mortality was recorded at 24 h for deltamethrin and pirimiphos-methyl, and 48 h for broflanilide. Resistance status classification follows WHO criteria: ≥ 98% mortality (susceptible), 90–97% (possible resistance), < 90% (confirmed resistance). Data represent mean percentage mortality ± standard deviation with 95% confidence intervals Susceptibility of field-collected An. gambiae s.l. and An. funestus s.l. to broflanilide, pirimiphos-methyl, and deltamethrin Susceptibility was determined using WHO bottle bioassays and CDC bottle bioassays. Mosquitoes were exposed to diagnostic concentrations: broflanilide (6 μg/bottle with 800 ppm Mero adjuvant), pirimiphos-methyl (20 μg/bottle), and deltamethrin (12.5 μg/bottle). Piperonyl butoxide (PBO) synergist assays used 4% PBO pre-exposure for 1 h before deltamethrin exposure. Mortality was recorded at 24 h for deltamethrin and pirimiphos-methyl, and 48 h for broflanilide. Resistance status classification follows WHO criteria: ≥ 98% mortality (susceptible), 90–97% (possible resistance), < 90% (confirmed resistance). Data represent mean percentage mortality ± standard deviation with 95% confidence intervals Wild vector pyrethroid mortality fell below WHO resistance thresholds. PBO pre-exposure restored susceptibility to some pyrethroids, with full susceptibility only to deltamethrin (100 ± 0%) and possible resistance to alpha-cypermethrin (97 ± 3.83%) in An. gambiae s.l. Significant mortality differences existed between An. gambiae s.l. and An. funestus (t₂ =− 5.52, p = 0.03) (Table 2). Adverse events and safety Throughout six months, 150 responses per intervention arm and five from negative controls were recorded. No adverse events were reported from VECTRON™ T500 households (0/150), while Actellic™ 300CS households reported adverse events in 8% of cases (12/150). Reported events included skin itchiness, facial burning, sneezing, eye irritation, and bad smell. Skin and facial burning was most frequent (2.7%, 4/150). All participants who developed adverse symptoms related to IRS product (Actellic™ 300CS) were treated at Siaya county referral hospital and the expenses of treatment and transport was covered by the study. Most adverse events occurred from spraying day to one-month post-spraying; none were reported after month 2. Community acceptability No statistically significant difference existed in future acceptability between VECTRON™ T500 (10.24% ± 12.25) and Actellic™ 300CS (9.16% ± 12.44) (t34 = 0.188, p = 0.852). Main VECTRON™ T500 acceptance factors were malaria reduction ability (48%, 72/150) and mosquito killing (31%, 47/150). For Actellic™ 300CS, malaria reduction was the primary reason (37%, 56/150). No refusals occurred in VECTRON™ T500 households throughout evaluation. Actellic™ 300CS had 4% refusal (1/25), attributed to insecticide odor. Most participants from both wall types expressed willingness for future VECTRON™ T500 spraying due to mosquito reduction. Discussion The high residual efficacy of VECTRON™ T500, maintaining > 95% mortality throughout six months against both susceptible and resistant An. gambiae s.s. mosquitoes, represents compelling evidence for its potential in western Kenya's high-resistance contexts. The consistent performance across wall types addresses a critical operational challenge, as mud surfaces often present alkaline pH and porosity that can degrade or sequester active ingredients [28, 29]. The findings are consistent with recent experimental hut studies conducted in Benin [30, 31] and Tanzania [32, 33], which demonstrated prolonged efficacy of VECTRON™ T500 against pyrethroid-resistant An. gambiae s.l. populations. The extended efficacy duration has significant programmatic implications. While Actellic™ 300CS would require reapplication after 4 months to maintain WHO-recommended efficacy thresholds in this context, VECTRON™ T500's sustained performance suggests potential for extended spray cycles. This could reduce operational costs, logistical demands, and household disruption while maintaining protection levels. Similar extended residual activity has been reported in experimental hut studies in Benin, where cone bioassay mortality remained > 80% for 18 months [30], and in Tanzania where efficacy persisted for 12 months [32]. Community trials in Benin demonstrated that VECTRON™ T500 maintained 100% mortality in wall cone bioassays for 24 months on both cement and mud walls [34]. Cost-effectiveness modelling based on these efficacy data would be valuable for programme planning. Assuming similar application costs, the extended efficacy could translate to substantial savings through reduced spray frequencies. However, formal economic evaluation incorporating product costs, application expenses, and health outcomes is needed to quantify potential savings. This study represents the first comprehensive field evaluation of VECTRON™ T500 against An. funestus s.l. populations. Previous evaluations have primarily focused on An. gambiae s.l. and An. arabiensis populations [30–33], with An. funestus either absent from study sites or present in insufficient numbers for meaningful analysis. A recent multi-centre discriminating concentration study specifically noted that "unfortunately, this was not feasible for inclusion due to notorious difficulties rearing this particular species under controlled insectary conditions" [35]. The complete susceptibility of wild An. funestus s.l. to broflanilide (100% mortality at 6 μg/bottle) documented in this study is particularly significant given the critical role this species plays in malaria transmission across eastern and southern Africa [36, 37], making the efficacy of VECTRON™ T500 against this species particularly valuable for elimination efforts. The GABA receptor targeting mechanism differs fundamentally from existing insecticide classes, providing genuine rotation options for sustainable resistance management [16, 38]. This finding aligns with previous laboratory and field studies that demonstrated no cross-resistance between broflanilide and pyrethroid resistance mechanisms in Burkina Faso, Benin, Tanzania [18, 30, 32, 33, 40], and now Kenya, suggesting broad applicability for resistance management across diverse vector populations. The absence of adverse events in VECTRON™ T500 households versus 8% in Actellic™ 300CS households, combined with 100% community acceptance, addresses critical implementation barriers. High refusal rates can compromise IRS coverage and effectiveness [41, 42]. The superior acceptability profile suggests VECTRON™ T500 could achieve better coverage in operational settings. This safety profile is consistent with findings from community trials in Benin [34] and Burkina Faso [40], where minimal to no adverse events were reported with VECTRON™ T500. The primary acceptance drivers (malaria reduction and mosquito killing effectiveness) align with actual product performance, indicating realistic community perceptions. This concordance between expectations and performance suggests sustainable acceptance in repeated spray cycles, as demonstrated in the Burkina Faso study where acceptance remained high throughout a 12-month evaluation period [40]. The performance of VECTRON™ T500 compares favorably with other recently developed IRS formulations. Experimental hut studies comparing VECTRON™ T500 with Actellic™ 300CS in Benin showed non-inferiority in terms of mosquito mortality, with VECTRON™ T500 demonstrating superior residual activity [30]. Similarly, community trials comparing VECTRON™ T500 with Fludora® Fusion in both Benin [34] and Tanzania [43] demonstrated non-inferiority in reducing vector densities while showing extended residual efficacy. The delayed mortality characteristic of VECTRON™ T500, attributed to its requirement for metabolic activation to desmethyl-broflanilide [16], has been observed consistently across studies. While this differs from the rapid knockdown effects of pyrethroids, modelling studies suggest that such slower-acting insecticides may be less likely to select for resistance [44], potentially extending their operational lifespan. Several limitations warrant consideration. The six-month evaluation period, while comprehensive for regulatory purposes, may not capture long-term resistance development or efficacy decline. Extended monitoring would strengthen evidence for operational decision-making. Furthermore, the absence of chemical analysis, which could have provided crucial information on the residual efficacy and chemical persistence of the IRS application, potentially informing future interventions and optimization strategies. Recent studies in Benin and Tanzania with longer follow-up periods (18–24 months) have shown sustained efficacy [30, 34], suggesting that the performance observed in this study would likely continue beyond six months. The study design used village-level allocation rather than household randomization, potentially introducing geographical confounding. However, the stratification by wall type and similar baseline characteristics minimize this risk. Cost-effectiveness analysis was beyond this study's scope but represents a critical knowledge gap for program planning. Superior efficacy must be balanced against potential cost differences for informed product selection. Seasonal variations in efficacy were not fully captured given the June-November study period. Year-round evaluation would provide more comprehensive efficacy profiles under varying environmental conditions, as demonstrated in the Burkina Faso study which showed consistent performance across both dry and wet seasons [40]. Conclusions VECTRON™ T500 demonstrated superior residual efficacy compared to Actellic™ 300CS, maintaining > 95% mortality throughout six months against both susceptible and pyrethroid-resistant An. gambiae s.s. strains. Importantly, this study provides the first comprehensive field evidence of VECTRON™ T500's efficacy against An. funestus s.l., showing complete susceptibility with no cross-resistance to pirimiphos-methyl and pyrethroids. The excellent safety profile with zero adverse events and 100% community acceptance collectively position VECTRON™ T500 as a valuable tool for malaria vector control programmes. The novel GABA receptor targeting mode of action provides genuine resistance management options, while extended residual activity offers potential operational advantages through reduced application frequency. These characteristics align with WHO Global Plan for Insecticide Resistance Management recommendations emphasizing rotation between insecticides with different modes of action [10]. The findings support incorporating VECTRON™ T500 into resistance management strategies for sustainable malaria vector control, particularly in areas with high pyrethroid resistance or where An. funestus s.l. contributes significantly to transmission. Superior performance profile, combined with evidence from other African settings, warrants consideration for national malaria control programme adoption, pending cost-effectiveness evaluation and regulatory approval.